Imugene Ltd managing director and CEO Dr. Leslie Chong talked with Proactive about encouraging new data from its ongoing Phase 1b clinical trial of azer-cel (azercabtagene zapreleucel), an allogeneic CAR T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Dr. Chong confirmed that five additional patients have been dosed since the company’s last update in February. Of these, two achieved complete responses—meaning no detectable cancer—and three showed partial responses with at least 50% tumour reduction. “They are living cancer-free,” said Chong, referring to the patients who had complete responses.
Chong explained that many patients enrolled had already failed multiple prior treatments, including autologous CAR-T therapy, underscoring the difficult-to-treat nature of the population. One patient is now 15 months cancer-free, supporting the durability of the response. Imugene highlighted that the trial continues to meet the FDA’s benchmark of a 50% response rate with at least six months’ durability.
Looking ahead, the company plans to expand the trial to include CAR-T naïve patients and explore earlier lines of therapy. Imugene also intends to seek regulatory feedback through a Type B End of Phase meeting with the FDA to discuss its registration strategy.
👉 For more interviews and company updates, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to our channel, and turn on notifications for future content.
5